Efprezimod alfa
Based on 1 Customer Validation
Efprezimod alfa (MK-7110; CD24 Fc) is a humanized CD24-Fc fusion protein. Efprezimod alfa enhances the interaction between CD24 and Siglec-10, thereby regulating the response of innate immune cells to damage-associated molecular patterns, inhibiting the activation of antigen-presenting cells and subsequent inflammatory responses. Efprezimod alfa is applicable to the research of acute graft-versus-host disease and acquired immunodeficiency syndrome.
For research use only. We do not sell to patients.
- Purity : 99.25%
- CAS No.: 2574508-57-7
- Molecular Weight:57.74 kDa
-
Storage:Shipping with dry ice
Please store the product under the recommended conditions in the Certificate of Analysis.
Biological Activity
Description
In Vitro
Fprezimod alfa enhances the interaction between CD24 and Siglec-10, thereby regulating the response of innate immune cells to damage-associated molecular patterns, and inhibiting the activation of antigen-presenting cells as well as subsequent inflammatory responses[1][2].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
Product Details
-
CAS No. 2574508-57-7
-
Synonyms MK-7110; CD24 Fc
-
Molecular Weight 57.74 kDa
-
Species Reactivity
Human
-
Conjugated
Unconjugated
-
Format
-
CD24 (CD24 molecule, CD24 antigen (small cell lung carcinoma cluster 4 antigen))-IGHG1 Fc (Fragment constant)
-
Product Properties
-
Appearance
Liquid
-
Formulation
Please refer to the lot-specific COA for specific buffer information.
-
Purity
99.25%
-
Reconstitution
The product can be reconstituted/diluted with sterile PBS or saline.
-
Storage & Stability
Please store the product under the recommended conditions in the Certificate of Analysis.
-
Shipping
Shipping with dry ice.
Purity & Documentation
References
[1]. Magenau J, et al. A phase 2 trial of CD24Fc for prevention of graft-versus-host disease. Blood. 2024 Jan 4;143(1):21-31. [Content Brief]
[2]. Du R, et al. Is modulation of immune checkpoints on glioblastoma-infiltrating myeloid cells a viable therapeutic strategy?. Neuro Oncol. 2025;27(1):33-49. [Content Brief]
Calculators
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)